Sign Out
Doxorubicin hydrochloride is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer.
Doxorubicin hydrochloride is indicated for the treatment of: acute lymphoblastic leukemia; acute myeloid leukemia; Hodgkin lymphoma; non-Hodgkin lymphoma (NHL); metastatic breast cancer; metastatic Wilms tumor; metastatic neuroblastoma; metastatic soft tissue sarcoma; metastatic bone sarcoma; metastatic ovarian carcinoma; metastatic transitional cell bladder carcinoma; metastatic thyroid carcinoma; metastatic gastric carcinoma; metastatic bronchogenic carcinoma.
